Which has stronger valuation and earnings, MBX or ABVX?

MBX Biosciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Abivax N/A N/A -$380.27M -$5.21 N/A

Is MBX or ABVX more profitable?

MBX Biosciences' return on equity of -24.52% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Abivax N/A -99.02% -70.26%

Does the media favor MBX or ABVX?

In the previous week, MBX Biosciences and MBX Biosciences both had 13 articles in the media. Abivax's average media sentiment score of 1.41 beat MBX Biosciences' score of 0.85 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 12 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, MBX or SMMT?

MBX Biosciences is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.21 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is MBX or SMMT more profitable?

MBX Biosciences' return on equity of -24.52% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -24.52% -23.59% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor MBX or SMMT?

In the previous week, MBX Biosciences and MBX Biosciences both had 13 articles in the media. MBX Biosciences' average media sentiment score of 0.85 beat Summit Therapeutics' score of 0.35 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor CYTK or MBX?

In the previous week, Cytokinetics had 10 more articles in the media than MBX Biosciences. MarketBeat recorded 23 mentions for Cytokinetics and 13 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.85 beat Cytokinetics' score of 0.79 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 14 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KRYS or MBX?

In the previous week, Krystal Biotech had 7 more articles in the media than MBX Biosciences. MarketBeat recorded 20 mentions for Krystal Biotech and 13 mentions for MBX Biosciences. Krystal Biotech's average media sentiment score of 1.17 beat MBX Biosciences' score of 0.85 indicating that Krystal Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 13 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend MBX or RDY?

MBX Biosciences presently has a consensus price target of $71.13, indicating a potential upside of 9.54%. Given MBX Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe MBX Biosciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 2 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.75 Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Does the media prefer MBX or RDY?

In the previous week, MBX Biosciences had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 13 mentions for MBX Biosciences and 7 mentions for Dr. Reddy's Laboratories. MBX Biosciences' average media sentiment score of 0.85 beat Dr. Reddy's Laboratories' score of 0.69 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 5 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MBX Biosciences (MBX) Competitors

$64.93 -1.00 (-1.52%)

As of 09:47 AM Eastern

Compare

MBX vs. ABVX, SMMT, CYTK, KRYS, and RDY

Should you buy MBX Biosciences stock or one of its competitors? MarketBeat compares MBX Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MBX Biosciences include Abivax (ABVX), Summit Therapeutics (SMMT), Cytokinetics (CYTK), Krystal Biotech (KRYS), and Dr. Reddy's Laboratories (RDY).

How does MBX Biosciences compare to Abivax?

MBX Biosciences (NASDAQ:MBX) and Abivax (NASDAQ:ABVX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

MBX Biosciences is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

47.9% of Abivax shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MBX Biosciences' return on equity of -24.52% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Abivax	N/A	-99.02%	-70.26%

MBX Biosciences presently has a consensus target price of $71.13, suggesting a potential upside of 9.54%. Abivax has a consensus target price of $156.50, suggesting a potential upside of 29.22%. Given Abivax's stronger consensus rating and higher possible upside, analysts clearly believe Abivax is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, MBX Biosciences and MBX Biosciences both had 13 articles in the media. Abivax's average media sentiment score of 1.41 beat MBX Biosciences' score of 0.85 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	12 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Abivax has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Summary

Abivax beats MBX Biosciences on 7 of the 13 factors compared between the two stocks.

How does MBX Biosciences compare to Summit Therapeutics?

MBX Biosciences (NASDAQ:MBX) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

4.6% of Summit Therapeutics shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MBX Biosciences has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market.

In the previous week, MBX Biosciences and MBX Biosciences both had 13 articles in the media. MBX Biosciences' average media sentiment score of 0.85 beat Summit Therapeutics' score of 0.35 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Summit Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

MBX Biosciences' return on equity of -24.52% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Summit Therapeutics	N/A	-168.94%	-141.92%

MBX Biosciences is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

MBX Biosciences presently has a consensus price target of $71.13, indicating a potential upside of 9.54%. Summit Therapeutics has a consensus price target of $26.15, indicating a potential upside of 102.94%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44

Summary

MBX Biosciences beats Summit Therapeutics on 7 of the 12 factors compared between the two stocks.

How does MBX Biosciences compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.

In the previous week, Cytokinetics had 10 more articles in the media than MBX Biosciences. MarketBeat recorded 23 mentions for Cytokinetics and 13 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.85 beat Cytokinetics' score of 0.79 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	14 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytokinetics currently has a consensus target price of $99.90, suggesting a potential upside of 30.98%. MBX Biosciences has a consensus target price of $71.13, suggesting a potential upside of 9.54%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities analysts plainly believe Cytokinetics is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.95
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

MBX Biosciences has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
MBX Biosciences	N/A	-24.52%	-23.59%

MBX Biosciences has lower revenue, but higher earnings than Cytokinetics. MBX Biosciences is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$105.82M	89.69	-$784.96M	-$6.84	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

Cytokinetics has a beta of 0.42, suggesting that its share price is 58% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market.

Summary

Cytokinetics beats MBX Biosciences on 9 of the 14 factors compared between the two stocks.

How does MBX Biosciences compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Krystal Biotech has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	24.33	$204.83M	$7.48	42.94
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A

86.3% of Krystal Biotech shares are owned by institutional investors. 13.1% of Krystal Biotech shares are owned by insiders. Comparatively, 31.1% of MBX Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Krystal Biotech had 7 more articles in the media than MBX Biosciences. MarketBeat recorded 20 mentions for Krystal Biotech and 13 mentions for MBX Biosciences. Krystal Biotech's average media sentiment score of 1.17 beat MBX Biosciences' score of 0.85 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	13 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech presently has a consensus price target of $360.67, suggesting a potential upside of 12.30%. MBX Biosciences has a consensus price target of $71.13, suggesting a potential upside of 9.54%. Given Krystal Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Krystal Biotech is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Krystal Biotech has a net margin of 53.92% compared to MBX Biosciences' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
MBX Biosciences	N/A	-24.52%	-23.59%

Krystal Biotech has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

Summary

Krystal Biotech beats MBX Biosciences on 14 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

MBX Biosciences (NASDAQ:MBX) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Dr. Reddy's Laboratories has a net margin of 10.15% compared to MBX Biosciences' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-24.52%	-23.59%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

Dr. Reddy's Laboratories has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.21	N/A
Dr. Reddy's Laboratories	$3.58B	2.82	$456M	$0.44	27.46

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MBX Biosciences has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

MBX Biosciences presently has a consensus price target of $71.13, indicating a potential upside of 9.54%. Given MBX Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe MBX Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

In the previous week, MBX Biosciences had 6 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 13 mentions for MBX Biosciences and 7 mentions for Dr. Reddy's Laboratories. MBX Biosciences' average media sentiment score of 0.85 beat Dr. Reddy's Laboratories' score of 0.69 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dr. Reddy's Laboratories beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBX vs. The Competition

Export

Metric	MBX Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.18B	$3.54B	$6.85B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-30.26	7.38	282.28	24.66
Price / Sales	N/A	1,199.83	563.21	75.35
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	7.90	16.96	10.96	6.07
Net Income	-$86.97M	-$12.56M	$3.49B	$347.99M
7 Day Performance	5.92%	-1.80%	-0.63%	-0.44%
1 Month Performance	12.33%	-8.44%	-5.23%	-4.81%
1 Year Performance	N/A	48.63%	62.07%	18.61%

MBX Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBX MBX Biosciences	1.9793 of 5 stars	$64.93 -1.5%	$71.13 +9.5%	N/A	$3.18B	N/A	N/A	N/A
ABVX Abivax	3.9321 of 5 stars	$125.70 -4.2%	$156.50 +24.5%	+73.6%	$10.96B	N/A	N/A	61	Positive News
SMMT Summit Therapeutics	3.4832 of 5 stars	$13.66 -8.8%	$26.15 +91.5%	-51.9%	$10.60B	N/A	N/A	110	Gap Up High Trading Volume
CYTK Cytokinetics	3.4909 of 5 stars	$80.74 -1.4%	$99.90 +23.7%	+110.2%	$10.05B	$88.04M	N/A	250	Positive News Upcoming Earnings
KRYS Krystal Biotech	3.2734 of 5 stars	$335.19 +2.3%	$360.67 +7.6%	+117.3%	$9.88B	$389.13M	44.81	210	News Coverage Positive News Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MBX Biosciences (MBX) Competitors

MBX vs. ABVX, SMMT, CYTK, KRYS, and RDY

How does MBX Biosciences compare to Abivax?

Summary

How does MBX Biosciences compare to Summit Therapeutics?

Summary

How does MBX Biosciences compare to Cytokinetics?

Summary

How does MBX Biosciences compare to Krystal Biotech?

Summary

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MBX Biosciences (MBX) Competitors

MBX vs. ABVX, SMMT, CYTK, KRYS, and RDY

How does MBX Biosciences compare to Abivax?

Which has stronger valuation and earnings, MBX or ABVX?

Do insiders and institutionals hold more shares of MBX or ABVX?

Is MBX or ABVX more profitable?

Do analysts prefer MBX or ABVX?

Does the media favor MBX or ABVX?

Which has more risk & volatility, MBX or ABVX?

Summary

How does MBX Biosciences compare to Summit Therapeutics?

Do insiders and institutionals believe in MBX or SMMT?

Which has more risk and volatility, MBX or SMMT?

Does the media favor MBX or SMMT?

Is MBX or SMMT more profitable?

Which has preferable earnings and valuation, MBX or SMMT?

Do analysts rate MBX or SMMT?

Summary

How does MBX Biosciences compare to Cytokinetics?

Does the media favor CYTK or MBX?

Do analysts rate CYTK or MBX?

Is CYTK or MBX more profitable?

Which has stronger valuation and earnings, CYTK or MBX?

Which has more volatility and risk, CYTK or MBX?

Summary

How does MBX Biosciences compare to Krystal Biotech?

Which has stronger earnings & valuation, KRYS or MBX?

Do institutionals and insiders hold more shares of KRYS or MBX?

Does the media refer more to KRYS or MBX?

Do analysts recommend KRYS or MBX?

Is KRYS or MBX more profitable?

Which has more volatility & risk, KRYS or MBX?

Summary

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Is MBX or RDY more profitable?

Which has better earnings & valuation, MBX or RDY?

Do insiders & institutionals believe in MBX or RDY?

Which has more volatility and risk, MBX or RDY?

Do analysts recommend MBX or RDY?

Does the media prefer MBX or RDY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools